Orion Biotechnology Shares In Vivo Efficacy Data on its Latest Best-in-Class Drug Candidate Ottawa, Canada, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G...

ORION BIOTECHNOLOGY ADDS GPCR EXPERT TO ITS SCIENTIFIC ADVISORY BOARD Ottawa, Canada, July 05, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a drug discovery and development company targeting previously-undruggable G Protein-Coupled Receptors (GPCRs), today...

ORION ANNOUNCES THE RAPID LEAD OPTIMIZATION OF OB-004 - A CCR2 ANTAGONIST Ottawa, Ontario, Canada, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology, a clinical stage company unlocking the therapeutic potential of  G Protein-Coupled Receptors (GPCRs) with a novel drug...

ORION BIOTECHNOLOGY RECEIVES FUNDING TO ADVANCE ITS LEAD GPCR-TARGETED THERAPEUTIC Ottawa, Canada, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel...